The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Oral decitabine with venetoclax versus oral decitabine alone in HR-MDS
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an analysis of oral decitabine combined with venetoclax versus decitabine alone in higher-risk myelodysplastic syndromes (HR-MDS). The study found that the combination therapy resulted in a higher and faster response rate but did not improve overall survival (OS). The Phase III VERONA trial (NCT04401748) is anticipated to provide data on azacitidine plus venetoclax in HR-MDS. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
